Here are the 10-K annual reports from Coya Therapeutics, Inc. (COYA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow COYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COYA filings page.
Coya Therapeutics, Inc. is a clinical-stage biotech focused on therapies that enhance regulatory T cells to treat neurodegenerative, autoimmune and metabolic diseases. Its lead biologic, COYA 302, is in a Phase 2 ALSTARS trial for ALS after FDA IND acceptance, with an additional IND cleared for frontotemporal dementia. The company is also advancing COYA 303 and the low-dose IL-2 backbone COYA 301, plus Treg-derived exosome programs.
Coya reported a 2025 net loss of $21.2 million, up from $14.9 million in 2024, and an accumulated deficit of $62.0 million as of December 31, 2025. In January 2026 it raised $11.1 million in gross proceeds, including $10 million from strategic collaborator Dr. Reddy's, and expects its cash runway to extend into the second half of 2027. Management nonetheless states it will need substantial additional capital and highlights going-concern uncertainty if funding is not obtained.